Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) Stock Competitors & Peer Comparison
See ITCI's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ITCI and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| TAK | $17.42 | -0.37% | 55.4B | 12.52 | $1.39 | +3.62% |
| HLN | $9.79 | -1.51% | 43.2B | 18.28 | $0.54 | +1.80% |
| TEVA | $37.04 | +1.54% | 42.8B | 12.54 | $2.93 | N/A |
| VTRS | $16.25 | -0.16% | 18.7B | 6.39 | $2.52 | +2.98% |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| ELAN | $22.60 | -0.59% | 11.1B | 20.91 | $1.06 | N/A |
| RDY | $12.42 | -0.24% | 10.3B | 20.30 | $0.61 | +0.67% |
| LNTH | $100.90 | +0.22% | 6.6B | 16.93 | $5.95 | N/A |
| AMRX | $17.84 | +4.33% | 5.6B | 19.62 | $0.90 | N/A |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
ITCI vs TAK Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, TAK has a market cap of 55.4B. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while TAK trades at $17.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas TAK's P/E ratio is 12.52. In terms of profitability, ITCI's ROE is -0.09%, compared to TAK's ROE of +0.02%. Regarding short-term risk, ITCI is less volatile compared to TAK. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check TAK's competition here
Haleon plc (NYSE: HLN)
ITCI vs HLN Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, HLN has a market cap of 43.2B. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while HLN trades at $9.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas HLN's P/E ratio is 18.28. In terms of profitability, ITCI's ROE is -0.09%, compared to HLN's ROE of +0.17%. Regarding short-term risk, ITCI is less volatile compared to HLN. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check HLN's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
ITCI vs TEVA Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, TEVA has a market cap of 42.8B. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while TEVA trades at $37.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas TEVA's P/E ratio is 12.54. In terms of profitability, ITCI's ROE is -0.09%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, ITCI is less volatile compared to TEVA. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check TEVA's competition here
Viatris Inc. (NASDAQ: VTRS)
ITCI vs VTRS Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, VTRS has a market cap of 18.7B. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while VTRS trades at $16.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas VTRS's P/E ratio is 6.39. In terms of profitability, ITCI's ROE is -0.09%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, ITCI is less volatile compared to VTRS. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check VTRS's competition here
Catalent, Inc. (NYSE: CTLT)
ITCI vs CTLT Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas CTLT's P/E ratio is -27.84. In terms of profitability, ITCI's ROE is -0.09%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, ITCI is less volatile compared to CTLT. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check CTLT's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
ITCI vs ELAN Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, ELAN has a market cap of 11.1B. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while ELAN trades at $22.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas ELAN's P/E ratio is 20.91. In terms of profitability, ITCI's ROE is -0.09%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, ITCI is less volatile compared to ELAN. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check ELAN's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
ITCI vs RDY Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, RDY has a market cap of 10.3B. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while RDY trades at $12.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas RDY's P/E ratio is 20.30. In terms of profitability, ITCI's ROE is -0.09%, compared to RDY's ROE of +0.09%. Regarding short-term risk, ITCI is less volatile compared to RDY. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check RDY's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
ITCI vs LNTH Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while LNTH trades at $100.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas LNTH's P/E ratio is 16.93. In terms of profitability, ITCI's ROE is -0.09%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, ITCI is less volatile compared to LNTH. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
ITCI vs AMRX Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, AMRX has a market cap of 5.6B. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while AMRX trades at $17.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas AMRX's P/E ratio is 19.62. In terms of profitability, ITCI's ROE is -0.09%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, ITCI is less volatile compared to AMRX. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check AMRX's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
ITCI vs INDV Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, INDV has a market cap of 4.8B. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while INDV trades at $38.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas INDV's P/E ratio is 10.61. In terms of profitability, ITCI's ROE is -0.09%, compared to INDV's ROE of -2.16%. Regarding short-term risk, ITCI is less volatile compared to INDV. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check INDV's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
ITCI vs SUPN Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, SUPN has a market cap of 2.8B. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while SUPN trades at $47.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas SUPN's P/E ratio is 15.64. In terms of profitability, ITCI's ROE is -0.09%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, ITCI is less volatile compared to SUPN. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check SUPN's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
ITCI vs RGC Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, RGC has a market cap of 2.5B. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while RGC trades at $5.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas RGC's P/E ratio is -356.34. In terms of profitability, ITCI's ROE is -0.09%, compared to RGC's ROE of -2.32%. Regarding short-term risk, ITCI is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check RGC's competition here
Bausch Health Companies Inc. (NYSE: BHC)
ITCI vs BHC Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, BHC has a market cap of 2.3B. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while BHC trades at $6.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas BHC's P/E ratio is 1.58. In terms of profitability, ITCI's ROE is -0.09%, compared to BHC's ROE of +0.89%. Regarding short-term risk, ITCI is less volatile compared to BHC. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check BHC's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
ITCI vs DCPH Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas DCPH's P/E ratio is -11.58. In terms of profitability, ITCI's ROE is -0.09%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, ITCI is less volatile compared to DCPH. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check DCPH's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
ITCI vs HCM Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, HCM has a market cap of 2.1B. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while HCM trades at $12.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas HCM's P/E ratio is 4.59. In terms of profitability, ITCI's ROE is -0.09%, compared to HCM's ROE of +0.01%. Regarding short-term risk, ITCI is less volatile compared to HCM. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check HCM's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
ITCI vs AVDL Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, ITCI's ROE is -0.09%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, ITCI is similarly volatile compared to AVDL. This indicates similar risk in terms of short-term price fluctuations for ITCI.Check AVDL's competition here
Embecta Corp. (NASDAQ: EMBCV)
ITCI vs EMBCV Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas EMBCV's P/E ratio is N/A. In terms of profitability, ITCI's ROE is -0.09%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, ITCI is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
ITCI vs DVAX Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas DVAX's P/E ratio is -41.89. In terms of profitability, ITCI's ROE is -0.09%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, ITCI is similarly volatile compared to DVAX. This indicates similar risk in terms of short-term price fluctuations for ITCI.Check DVAX's competition here
Perrigo Company plc (NYSE: PRGO)
ITCI vs PRGO Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, PRGO has a market cap of 1.8B. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while PRGO trades at $12.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas PRGO's P/E ratio is 5.07. In terms of profitability, ITCI's ROE is -0.09%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, ITCI is less volatile compared to PRGO. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check PRGO's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
ITCI vs ANIP Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while ANIP trades at $75.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas ANIP's P/E ratio is 9.14. In terms of profitability, ITCI's ROE is -0.09%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, ITCI is less volatile compared to ANIP. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check ANIP's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
ITCI vs TARO Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas TARO's P/E ratio is 30.05. In terms of profitability, ITCI's ROE is -0.09%, compared to TARO's ROE of +0.03%. Regarding short-term risk, ITCI is less volatile compared to TARO. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check TARO's competition here
Harrow Health, Inc. (NASDAQ: HROW)
ITCI vs HROW Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, HROW has a market cap of 1.5B. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while HROW trades at $39.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas HROW's P/E ratio is 437.33. In terms of profitability, ITCI's ROE is -0.09%, compared to HROW's ROE of -1.04%. Regarding short-term risk, ITCI is less volatile compared to HROW. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check HROW's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
ITCI vs PAHC Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while PAHC trades at $34.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas PAHC's P/E ratio is 11.54. In terms of profitability, ITCI's ROE is -0.09%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, ITCI is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check PAHC's competition here
Alvotech (NASDAQ: ALVO)
ITCI vs ALVO Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, ALVO has a market cap of 1.4B. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while ALVO trades at $3.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas ALVO's P/E ratio is -11.79. In terms of profitability, ITCI's ROE is -0.09%, compared to ALVO's ROE of +0.35%. Regarding short-term risk, ITCI is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check ALVO's competition here
Cronos Group Inc. (NASDAQ: CRON)
ITCI vs CRON Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while CRON trades at $3.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas CRON's P/E ratio is 30.10. In terms of profitability, ITCI's ROE is -0.09%, compared to CRON's ROE of +0.06%. Regarding short-term risk, ITCI is less volatile compared to CRON. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check CRON's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
ITCI vs ETON Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, ETON has a market cap of 1.1B. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while ETON trades at $42.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas ETON's P/E ratio is -594.00. In terms of profitability, ITCI's ROE is -0.09%, compared to ETON's ROE of -0.06%. Regarding short-term risk, ITCI is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check ETON's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
ITCI vs PCRX Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, PCRX has a market cap of 932.2M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while PCRX trades at $23.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas PCRX's P/E ratio is 9.12. In terms of profitability, ITCI's ROE is -0.09%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, ITCI is less volatile compared to PCRX. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check PCRX's competition here
PetIQ, Inc. (NASDAQ: PETQ)
ITCI vs PETQ Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas PETQ's P/E ratio is 83.73. In terms of profitability, ITCI's ROE is -0.09%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, ITCI is less volatile compared to PETQ. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check PETQ's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
ITCI vs AMPH Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, AMPH has a market cap of 881M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while AMPH trades at $20.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas AMPH's P/E ratio is 6.82. In terms of profitability, ITCI's ROE is -0.09%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, ITCI is less volatile compared to AMPH. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check AMPH's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
ITCI vs COLL Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, COLL has a market cap of 842.6M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while COLL trades at $28.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas COLL's P/E ratio is 3.26. In terms of profitability, ITCI's ROE is -0.09%, compared to COLL's ROE of +0.16%. Regarding short-term risk, ITCI is less volatile compared to COLL. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check COLL's competition here
Evotec SE (NASDAQ: EVO)
ITCI vs EVO Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, EVO has a market cap of 778M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while EVO trades at $2.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas EVO's P/E ratio is -3.09. In terms of profitability, ITCI's ROE is -0.09%, compared to EVO's ROE of -0.24%. Regarding short-term risk, ITCI is less volatile compared to EVO. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check EVO's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
ITCI vs IRWD Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, IRWD has a market cap of 711.1M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while IRWD trades at $4.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas IRWD's P/E ratio is 5.54. In terms of profitability, ITCI's ROE is -0.09%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, ITCI is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check IRWD's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
ITCI vs BDSI Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas BDSI's P/E ratio is 6.82. In terms of profitability, ITCI's ROE is -0.09%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, ITCI is less volatile compared to BDSI. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check BDSI's competition here
Evolus, Inc. (NASDAQ: EOLS)
ITCI vs EOLS Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, EOLS has a market cap of 534.7M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while EOLS trades at $8.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas EOLS's P/E ratio is -25.71. In terms of profitability, ITCI's ROE is -0.09%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, ITCI is less volatile compared to EOLS. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check EOLS's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
ITCI vs AQST Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, AQST has a market cap of 530.7M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while AQST trades at $4.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas AQST's P/E ratio is -6.93. In terms of profitability, ITCI's ROE is -0.09%, compared to AQST's ROE of +2.44%. Regarding short-term risk, ITCI is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check AQST's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
ITCI vs TLRY Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, TLRY has a market cap of 523.4M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while TLRY trades at $4.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas TLRY's P/E ratio is -4.32. In terms of profitability, ITCI's ROE is -0.09%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, ITCI is less volatile compared to TLRY. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check TLRY's competition here
Canopy Growth Corporation (NASDAQ: CGC)
ITCI vs CGC Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, CGC has a market cap of 432.7M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while CGC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas CGC's P/E ratio is -0.62. In terms of profitability, ITCI's ROE is -0.09%, compared to CGC's ROE of -0.33%. Regarding short-term risk, ITCI is less volatile compared to CGC. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check CGC's competition here
Kamada Ltd. (NASDAQ: KMDA)
ITCI vs KMDA Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, KMDA has a market cap of 396.9M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while KMDA trades at $7.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas KMDA's P/E ratio is 19.66. In terms of profitability, ITCI's ROE is -0.09%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, ITCI is less volatile compared to KMDA. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check KMDA's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
ITCI vs TKNO Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, TKNO has a market cap of 396.2M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while TKNO trades at $7.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas TKNO's P/E ratio is -23.84. In terms of profitability, ITCI's ROE is -0.09%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, ITCI is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check TKNO's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
ITCI vs ALIM Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas ALIM's P/E ratio is 5.28. In terms of profitability, ITCI's ROE is -0.09%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, ITCI is less volatile compared to ALIM. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check ALIM's competition here
Embecta Corp. (NASDAQ: EMBC)
ITCI vs EMBC Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, EMBC has a market cap of 281.8M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while EMBC trades at $5.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas EMBC's P/E ratio is 1.83. In terms of profitability, ITCI's ROE is -0.09%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, ITCI is less volatile compared to EMBC. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check EMBC's competition here
Landec Corporation (NASDAQ: LNDC)
ITCI vs LNDC Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas LNDC's P/E ratio is -4.04. In terms of profitability, ITCI's ROE is -0.09%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, ITCI is less volatile compared to LNDC. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check LNDC's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
ITCI vs ACB Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, ACB has a market cap of 236.6M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while ACB trades at $3.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas ACB's P/E ratio is -7.80. In terms of profitability, ITCI's ROE is -0.09%, compared to ACB's ROE of -0.21%. Regarding short-term risk, ITCI is less volatile compared to ACB. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check ACB's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
ITCI vs ORGO Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, ORGO has a market cap of 232.9M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while ORGO trades at $1.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas ORGO's P/E ratio is 60.33. In terms of profitability, ITCI's ROE is -0.09%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, ITCI is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check ORGO's competition here
Shineco, Inc. (NASDAQ: TYHT)
ITCI vs TYHT Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas TYHT's P/E ratio is -1.61. In terms of profitability, ITCI's ROE is -0.09%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, ITCI is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check TYHT's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
ITCI vs SIGA Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, SIGA has a market cap of 205.8M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while SIGA trades at $2.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas SIGA's P/E ratio is 10.63. In terms of profitability, ITCI's ROE is -0.09%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, ITCI is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check SIGA's competition here
Organigram Global Inc. (NASDAQ: OGI)
ITCI vs OGI Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, OGI has a market cap of 181.6M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while OGI trades at $1.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas OGI's P/E ratio is -4.96. In terms of profitability, ITCI's ROE is -0.09%, compared to OGI's ROE of -0.07%. Regarding short-term risk, ITCI is less volatile compared to OGI. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check OGI's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
ITCI vs LFCR Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, LFCR has a market cap of 178.9M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while LFCR trades at $4.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas LFCR's P/E ratio is -4.46. In terms of profitability, ITCI's ROE is -0.09%, compared to LFCR's ROE of -2.51%. Regarding short-term risk, ITCI is less volatile compared to LFCR. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check LFCR's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
ITCI vs REPH Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas REPH's P/E ratio is -8.04. In terms of profitability, ITCI's ROE is -0.09%, compared to REPH's ROE of -0.22%. Regarding short-term risk, ITCI is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check REPH's competition here
Journey Medical Corporation (NASDAQ: DERM)
ITCI vs DERM Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, DERM has a market cap of 177M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while DERM trades at $6.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas DERM's P/E ratio is -17.38. In terms of profitability, ITCI's ROE is -0.09%, compared to DERM's ROE of -0.36%. Regarding short-term risk, ITCI is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check DERM's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
ITCI vs CRDL Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, CRDL has a market cap of 175.2M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while CRDL trades at $1.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas CRDL's P/E ratio is -5.41. In terms of profitability, ITCI's ROE is -0.09%, compared to CRDL's ROE of -2.29%. Regarding short-term risk, ITCI is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check CRDL's competition here
Theratechnologies Inc. (NASDAQ: THTX)
ITCI vs THTX Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas THTX's P/E ratio is -28.83. In terms of profitability, ITCI's ROE is -0.09%, compared to THTX's ROE of +0.17%. Regarding short-term risk, ITCI is less volatile compared to THTX. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
ITCI vs ASRT Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas ASRT's P/E ratio is -7.10. In terms of profitability, ITCI's ROE is -0.09%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, ITCI is less volatile compared to ASRT. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check ASRT's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
ITCI vs CPIX Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, CPIX has a market cap of 119.3M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while CPIX trades at $7.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas CPIX's P/E ratio is -19.90. In terms of profitability, ITCI's ROE is -0.09%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, ITCI is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check CPIX's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
ITCI vs SCTL Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas SCTL's P/E ratio is -7.86. In terms of profitability, ITCI's ROE is -0.09%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, ITCI is less volatile compared to SCTL. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check SCTL's competition here
BGM Group Ltd. (NASDAQ: BGM)
ITCI vs BGM Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, BGM has a market cap of 111.9M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while BGM trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas BGM's P/E ratio is -1.01. In terms of profitability, ITCI's ROE is -0.09%, compared to BGM's ROE of -0.07%. Regarding short-term risk, ITCI is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check BGM's competition here
Procaps Group S.A. (NASDAQ: PROC)
ITCI vs PROC Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas PROC's P/E ratio is 1.53. In terms of profitability, ITCI's ROE is -0.09%, compared to PROC's ROE of -2.22%. Regarding short-term risk, ITCI is similarly volatile compared to PROC. This indicates similar risk in terms of short-term price fluctuations for ITCI.Check PROC's competition here
OptiNose, Inc. (NASDAQ: OPTN)
ITCI vs OPTN Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas OPTN's P/E ratio is -4.42. In terms of profitability, ITCI's ROE is -0.09%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, ITCI is similarly volatile compared to OPTN. This indicates similar risk in terms of short-term price fluctuations for ITCI.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
ITCI vs ZOM Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas ZOM's P/E ratio is -1.62. In terms of profitability, ITCI's ROE is -0.09%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, ITCI is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
ITCI vs GRVI Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas GRVI's P/E ratio is 26.05. In terms of profitability, ITCI's ROE is -0.09%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, ITCI is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check GRVI's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
ITCI vs ZYBT Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, ZYBT has a market cap of 73.5M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while ZYBT trades at $1.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas ZYBT's P/E ratio is -7.05. In terms of profitability, ITCI's ROE is -0.09%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, ITCI is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check ZYBT's competition here
Talphera, Inc. (NASDAQ: TLPH)
ITCI vs TLPH Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, TLPH has a market cap of 72.7M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while TLPH trades at $1.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas TLPH's P/E ratio is -4.52. In terms of profitability, ITCI's ROE is -0.09%, compared to TLPH's ROE of -0.93%. Regarding short-term risk, ITCI is less volatile compared to TLPH. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check TLPH's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
ITCI vs ZYNE Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, ITCI's ROE is -0.09%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, ITCI is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
ITCI vs SSIC Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas SSIC's P/E ratio is 11.93. In terms of profitability, ITCI's ROE is -0.09%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, ITCI is less volatile compared to SSIC. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check SSIC's competition here
The Valens Company Inc. (NASDAQ: VLNS)
ITCI vs VLNS Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas VLNS's P/E ratio is -1.03. In terms of profitability, ITCI's ROE is -0.09%, compared to VLNS's ROE of N/A. Regarding short-term risk, ITCI is less volatile compared to VLNS. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check VLNS's competition here
DURECT Corporation (NASDAQ: DRRX)
ITCI vs DRRX Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas DRRX's P/E ratio is -4.44. In terms of profitability, ITCI's ROE is -0.09%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, ITCI is similarly volatile compared to DRRX. This indicates similar risk in terms of short-term price fluctuations for ITCI.Check DRRX's competition here
InterCure Ltd. (NASDAQ: INCR)
ITCI vs INCR Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, INCR has a market cap of 57.1M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while INCR trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas INCR's P/E ratio is -2.23. In terms of profitability, ITCI's ROE is -0.09%, compared to INCR's ROE of -0.09%. Regarding short-term risk, ITCI is less volatile compared to INCR. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check INCR's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
ITCI vs JUPW Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas JUPW's P/E ratio is -2.41. In terms of profitability, ITCI's ROE is -0.09%, compared to JUPW's ROE of -1.94%. Regarding short-term risk, ITCI is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check JUPW's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
ITCI vs CPHI Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, CPHI has a market cap of 44.6M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while CPHI trades at $1.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas CPHI's P/E ratio is -1.72. In terms of profitability, ITCI's ROE is -0.09%, compared to CPHI's ROE of -0.19%. Regarding short-term risk, ITCI is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check CPHI's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
ITCI vs QLI Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas QLI's P/E ratio is -4.92. In terms of profitability, ITCI's ROE is -0.09%, compared to QLI's ROE of -0.16%. Regarding short-term risk, ITCI is similarly volatile compared to QLI. This indicates similar risk in terms of short-term price fluctuations for ITCI.Check QLI's competition here
HEXO Corp. (NASDAQ: HEXO)
ITCI vs HEXO Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas HEXO's P/E ratio is -0.26. In terms of profitability, ITCI's ROE is -0.09%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, ITCI is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check HEXO's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
ITCI vs RMTI Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, RMTI has a market cap of 30.8M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while RMTI trades at $7.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas RMTI's P/E ratio is -7.42. In terms of profitability, ITCI's ROE is -0.09%, compared to RMTI's ROE of -0.15%. Regarding short-term risk, ITCI is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check RMTI's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
ITCI vs AYTU Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, AYTU has a market cap of 25.3M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while AYTU trades at $2.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas AYTU's P/E ratio is -1.23. In terms of profitability, ITCI's ROE is -0.09%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, ITCI is less volatile compared to AYTU. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check AYTU's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
ITCI vs TXMD Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, TXMD has a market cap of 24.1M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while TXMD trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas TXMD's P/E ratio is 105.96. In terms of profitability, ITCI's ROE is -0.09%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, ITCI is less volatile compared to TXMD. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check TXMD's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
ITCI vs CYTH Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas CYTH's P/E ratio is -0.80. In terms of profitability, ITCI's ROE is -0.09%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, ITCI is similarly volatile compared to CYTH. This indicates similar risk in terms of short-term price fluctuations for ITCI.Check CYTH's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
ITCI vs EVOK Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas EVOK's P/E ratio is -7.97. In terms of profitability, ITCI's ROE is -0.09%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, ITCI is similarly volatile compared to EVOK. This indicates similar risk in terms of short-term price fluctuations for ITCI.Check EVOK's competition here
Optimi Health Corp. (NASDAQ: OPTH)
ITCI vs OPTH Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, OPTH has a market cap of 15.3M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while OPTH trades at $4.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas OPTH's P/E ratio is -17.38. In terms of profitability, ITCI's ROE is -0.09%, compared to OPTH's ROE of -0.94%. Regarding short-term risk, ITCI is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
ITCI vs ACRX Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas ACRX's P/E ratio is -0.31. In terms of profitability, ITCI's ROE is -0.09%, compared to ACRX's ROE of -0.93%. Regarding short-term risk, ITCI is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check ACRX's competition here
Biofrontera Inc. (NASDAQ: BFRIW)
ITCI vs BFRIW Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, BFRIW has a market cap of 13.3M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while BFRIW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas BFRIW's P/E ratio is -0.02. In terms of profitability, ITCI's ROE is -0.09%, compared to BFRIW's ROE of -4.77%. Regarding short-term risk, ITCI is less volatile compared to BFRIW. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check BFRIW's competition here
Cosmos Health Inc. (NASDAQ: COSM)
ITCI vs COSM Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, COSM has a market cap of 11.7M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while COSM trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas COSM's P/E ratio is -0.29. In terms of profitability, ITCI's ROE is -0.09%, compared to COSM's ROE of -0.96%. Regarding short-term risk, ITCI is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check COSM's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
ITCI vs AGRX Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas AGRX's P/E ratio is -0.89. In terms of profitability, ITCI's ROE is -0.09%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, ITCI is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
ITCI vs NLTX Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas NLTX's P/E ratio is -0.28. In terms of profitability, ITCI's ROE is -0.09%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, ITCI is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
ITCI vs LCI Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas LCI's P/E ratio is -0.04. In terms of profitability, ITCI's ROE is -0.09%, compared to LCI's ROE of +1.66%. Regarding short-term risk, ITCI is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
ITCI vs ADMP Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas ADMP's P/E ratio is -0.08. In terms of profitability, ITCI's ROE is -0.09%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, ITCI is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check ADMP's competition here
cbdMD, Inc. (AMEX: YCBD)
ITCI vs YCBD Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, YCBD has a market cap of 6.3M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while YCBD trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas YCBD's P/E ratio is -1.49. In terms of profitability, ITCI's ROE is -0.09%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, ITCI is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check YCBD's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
ITCI vs GELS Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, GELS has a market cap of 5.2M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while GELS trades at $0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas GELS's P/E ratio is -1.14. In terms of profitability, ITCI's ROE is -0.09%, compared to GELS's ROE of -0.25%. Regarding short-term risk, ITCI is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check GELS's competition here
Mallinckrodt plc (AMEX: MNK)
ITCI vs MNK Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas MNK's P/E ratio is -0.44. In terms of profitability, ITCI's ROE is -0.09%, compared to MNK's ROE of -0.36%. Regarding short-term risk, ITCI is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
ITCI vs FLGC Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas FLGC's P/E ratio is -0.19. In terms of profitability, ITCI's ROE is -0.09%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, ITCI is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check FLGC's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
ITCI vs UPC Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, UPC has a market cap of 3.8M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while UPC trades at $5.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas UPC's P/E ratio is -0.75. In terms of profitability, ITCI's ROE is -0.09%, compared to UPC's ROE of -0.03%. Regarding short-term risk, ITCI is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check UPC's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFM)
ITCI vs SBFM Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, SBFM has a market cap of 2.9M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while SBFM trades at $1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas SBFM's P/E ratio is -0.20. In terms of profitability, ITCI's ROE is -0.09%, compared to SBFM's ROE of -0.26%. Regarding short-term risk, ITCI is less volatile compared to SBFM. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check SBFM's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
ITCI vs PLXP Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas PLXP's P/E ratio is -0.22. In terms of profitability, ITCI's ROE is -0.09%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, ITCI is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check PLXP's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
ITCI vs SHPH Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, SHPH has a market cap of 2.5M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while SHPH trades at $4.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas SHPH's P/E ratio is -0.20. In terms of profitability, ITCI's ROE is -0.09%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, ITCI is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check SHPH's competition here
Athenex, Inc. (NASDAQ: ATNX)
ITCI vs ATNX Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas ATNX's P/E ratio is -0.02. In terms of profitability, ITCI's ROE is -0.09%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, ITCI is similarly volatile compared to ATNX. This indicates similar risk in terms of short-term price fluctuations for ITCI.Check ATNX's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
ITCI vs SNOA Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, SNOA has a market cap of 2.3M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while SNOA trades at $1.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas SNOA's P/E ratio is -1.16. In terms of profitability, ITCI's ROE is -0.09%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, ITCI is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check SNOA's competition here
Procaps Group, S.A. (NASDAQ: PROCW)
ITCI vs PROCW Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, PROCW has a market cap of 2M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while PROCW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas PROCW's P/E ratio is N/A. In terms of profitability, ITCI's ROE is -0.09%, compared to PROCW's ROE of -2.22%. Regarding short-term risk, ITCI is similarly volatile compared to PROCW. This indicates similar risk in terms of short-term price fluctuations for ITCI.Check PROCW's competition here
RedHill Biopharma Ltd. (NASDAQ: RDHL)
ITCI vs RDHL Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, RDHL has a market cap of 1.9M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while RDHL trades at $0.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas RDHL's P/E ratio is 0.12. In terms of profitability, ITCI's ROE is -0.09%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, ITCI is less volatile compared to RDHL. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check RDHL's competition here
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC)
ITCI vs SXTC Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, SXTC has a market cap of 1.8M. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while SXTC trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas SXTC's P/E ratio is 1.18. In terms of profitability, ITCI's ROE is -0.09%, compared to SXTC's ROE of -0.31%. Regarding short-term risk, ITCI is less volatile compared to SXTC. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check SXTC's competition here
cbdMD, Inc. (AMEX: YCBD-PA)
ITCI vs YCBD-PA Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, YCBD-PA has a market cap of 928.2K. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while YCBD-PA trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas YCBD-PA's P/E ratio is -2.69. In terms of profitability, ITCI's ROE is -0.09%, compared to YCBD-PA's ROE of -0.34%. Regarding short-term risk, ITCI is less volatile compared to YCBD-PA. This indicates lower risk in terms of short-term price fluctuations for ITCI.Check YCBD-PA's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTHW)
ITCI vs CYTHW Comparison August 2026
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ITCI stands at 14B. In comparison, CYTHW has a market cap of 928K. Regarding current trading prices, ITCI is priced at $131.87 on the NASDAQ, while CYTHW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ITCI currently has a P/E ratio of -180.64, whereas CYTHW's P/E ratio is N/A. In terms of profitability, ITCI's ROE is -0.09%, compared to CYTHW's ROE of -7.30%. Regarding short-term risk, ITCI is similarly volatile compared to CYTHW. This indicates similar risk in terms of short-term price fluctuations for ITCI.Check CYTHW's competition here